Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Multiple Oral Doses of RDN-929 in Healthy Older Adults

NCT03963973 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT03963973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03963973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Multiple Oral Doses of RDN-929 in Healthy Older Adults
Lead sponsor
Alkermes, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 16, 2019
Completion date
January 22, 2020
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy